Jacob P Thyssen

1. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
   2023/03/30 by Andrew Blauvelt, Jacob P. Thyssen, Jacob P Thyssen +19 · 26 citations
   Medicine · Immunology and Microbiology · #Dermatology and Skin Diseases #Psoriasis: Treatment and Pathogenesis #Asthma and respiratory diseases